Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.
Endocrinologists from both sectors (public and private) are participating in the study. Data will be captured electronically by DACIMA Clinical Suite, according to FDA 21 CFR part 11 (Food and Drug Administration 21 Code of Federal Regulations part 11), HIPAA (Health Insurance Portability and Accountability Act) \& ICH (International Conference on Harmonisation) requirements.
Study Type
OBSERVATIONAL
Enrollment
1,000
Société Tunisienne D'endocrinologie De Diabétologie Et Des Maladies Métaboliques
Sfax, Tunisia, Tunisia
Incidence of primary hypoparathyroidism
Number of subjects with primary hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of congenital hypoparathyroidism
Number of subjects with congenital hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of acquired hypoparathyroidism
Number of subjects with acquired hypoparathyroidism at enrollment
Time frame: Day 1
Incidence of secondary hypoparathyroidism
Number of subjects with secondary hypoparathyroidism at enrollment
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.